**Table 2: Characteristics of patients included in the meta-analysis**

|  |  |  |  |
| --- | --- | --- | --- |
|  | Deftereos *et al* 2020 | Lopes *et al* 2020 | Scarsi *et al* 2020 |
| Colchicine | No colchicine | Colchicine | No colchicine | colchicine | No colchicine |
| Patient characteristics | n=55Male- 31Female- 24Median age (IQR)- 63 (55 to 70) | n=50Male- 30Female- 20Median age (IQR)- 65 954 to 80) | n= 17Male- 9Female- 8Median age (IQR)-48 (41.5 to 64) | n= 18Male- 5Female- 13Median age (IQR)-53.5 (35.5 to 65.5) | n=122Male- 77Female- 45Mean age (SD)- 69.3 (9.6) | n=140Male- 90Female- 50Mean age (SD)- 70.5 (13.8) |
| Clinical deterioration (Primary outcome) | 1 | 7 | 1 | 1 | 20 | 52 |
| Development of adverse effect (Secondary outcome)  | 25 | 9 | 4 | 1 | 9 | 0 |
| Comorbidities[ n (%)] | Hypertension 22 (40)Diabetes 9 (16)Coronary artery disease9 (16)Respiratory disease3 (5) | Hypertension 25 (50)Diabetes 12 (24)Coronary artery disease5 (10)Respiratory disease2 (4) | Diabetes 5 (29)Coronary artery disease8 (47)Respiratory disease3 (18) | Diabetes 6(33)Coronary artery disease6 (33)Respiratory disease2 (11) | Coronary artery disease65(64)Respiratory disease17(17) | Coronary artery disease85(74)Respiratory disease24(22) |
| Additional treatment received | Hydroxychloroquine, Azithromycin, Lpinavir, Tocilizumab, Anticoagulant | Hydroxychloroquine, Azithromycin, Lpinavir, Tocilizumab, Anticoagulant | Hydroxychloroquine, Azithromycin, Heparin, Steroid | Hydroxychloroquine, AzithromycinHeparin, Steroid | Hydroxychlorquine, Lopinavir, Steroid | Hydroxychlorquine, Lopinavir, Steroid |